STAAR Surgical Company (STAA) Income Statement Analysis

See more : FDC Limited (FDC.NS) Income Statement Analysis – Financial Results

Complete financial analysis of STAAR Surgical Company (STAA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of STAAR Surgical Company, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.

You may be interested

BetterLife Holding Limited (6909.HK) Income Statement Analysis – Financial Results
Royal Orchid Hotels Limited (ROHLTD.NS) Income Statement Analysis – Financial Results
Axis Real Estate Investment Trust (5106.KL) Income Statement Analysis – Financial Results
Korean Air Lines Co., Ltd. (003495.KS) Income Statement Analysis – Financial Results
Nippon Gas Co., Ltd. (NPPGF) Income Statement Analysis – Financial Results

STAAR Surgical Company (STAA)

Industry: Medical - Instruments & Supplies

Sector: Healthcare

Website: https://www.staar.com

About STAAR Surgical Company

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988
Revenue	322.42M	284.39M	230.47M	163.46M	150.19M	123.95M	90.61M	82.43M	77.12M	74.99M	72.22M	63.78M	62.77M	54.96M	75.35M	74.89M	59.36M	56.28M	51.30M	51.69M	50.46M	48.25M	50.24M	53.99M	59.00M	54.20M	42.50M	42.20M	34.70M	27.40M	20.10M	10.20M	4.30M	4.50M	4.50M	6.80M
Cost of Revenue	69.76M	61.01M	51.84M	45.10M	38.23M	32.44M	26.33M	24.06M	24.40M	26.16M	21.91M	19.49M	20.40M	19.88M	33.45M	34.79M	30.10M	29.85M	27.52M	25.54M	22.62M	24.10M	28.20M	22.60M	18.70M	14.10M	6.80M	7.90M	6.90M	4.80M	3.10M	2.40M	2.00M	2.00M	7.20M	8.00M
Gross Profit	252.65M	223.38M	178.64M	118.36M	111.95M	91.51M	64.28M	58.37M	52.72M	48.82M	50.31M	44.29M	42.37M	35.08M	41.89M	40.11M	29.27M	26.43M	23.79M	26.14M	27.84M	24.15M	22.03M	31.39M	40.30M	40.10M	35.70M	34.30M	27.80M	22.60M	17.00M	7.80M	2.30M	2.50M	-2.70M	-1.20M
Gross Profit Ratio	78.36%	78.55%	77.51%	72.41%	74.54%	73.83%	70.94%	70.81%	68.36%	65.11%	69.67%	69.44%	67.50%	63.82%	55.60%	53.55%	49.30%	46.97%	46.36%	50.58%	55.17%	50.05%	43.86%	58.14%	68.31%	73.99%	84.00%	81.28%	80.12%	82.48%	84.58%	76.47%	53.49%	55.56%	-60.00%	-17.65%
Research & Development	44.40M	35.98M	33.86M	31.92M	25.30M	22.03M	19.12M	20.29M	14.76M	12.36M	6.71M	6.44M	5.87M	5.72M	5.89M	7.94M	6.71M	7.08M	5.57M	6.25M	5.12M	4.02M	3.80M	4.22M	4.30M	3.60M	3.90M	4.10M	3.30M	2.70M	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	72.32M	54.74M	44.14M	33.91M	29.31M	24.29M	20.67M	22.25M	19.60M	18.48M	18.81M	17.79M	15.99M	14.08M	15.71M	15.73M	12.95M	9.34M	9.34M	9.34M	9.34M	0.00	8.75M	8.59M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	107.83M	88.86M	67.29M	45.76M	45.49M	38.60M	28.13M	28.48M	23.70M	25.88M	23.89M	21.28M	17.73M	17.18M	24.26M	27.05M	23.72M	19.51M	19.51M	19.51M	19.51M	0.00	20.04M	21.25M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	180.15M	143.60M	111.44M	79.68M	74.80M	62.89M	48.80M	50.73M	43.30M	44.36M	42.70M	39.07M	33.72M	31.25M	39.97M	42.78M	36.67M	33.29M	29.03M	30.06M	29.24M	25.79M	28.79M	43.62M	27.80M	25.50M	19.00M	17.80M	15.90M	13.10M	14.20M	11.60M	12.90M	6.10M	0.00	0.00
Other Expenses	0.00	1.26M	967.00K	396.00K	703.00K	715.00K	628.00K	470.00K	759.00K	381.00K	486.00K	822.00K	0.00	700.00K	-238.00K	9.77M	0.00	-331.00K	0.00	0.00	0.00	1.45M	0.00	3.73M	4.20M	4.40M	3.50M	2.30M	1.50M	1.30M	900.00K	800.00K	600.00K	500.00K	900.00K	1.50M
Operating Expenses	224.55M	179.58M	145.30M	111.59M	100.10M	84.92M	67.91M	71.02M	58.06M	56.85M	49.61M	45.51M	39.59M	37.68M	45.62M	60.49M	43.39M	40.04M	34.60M	36.30M	34.36M	31.26M	32.59M	51.57M	36.30M	33.50M	26.40M	24.20M	20.70M	17.10M	15.10M	12.40M	13.50M	6.60M	900.00K	1.50M
Cost & Expenses	294.32M	240.59M	197.13M	156.69M	138.33M	117.36M	94.24M	95.09M	82.46M	83.01M	71.52M	65.00M	59.98M	57.56M	79.07M	95.28M	73.48M	69.88M	62.12M	61.84M	56.98M	55.36M	60.79M	74.17M	55.00M	47.60M	33.20M	32.10M	27.60M	21.90M	18.20M	14.80M	15.50M	8.60M	8.10M	9.50M
Interest Income	0.00	2.45M	38.00K	238.00K	988.00K	165.00K	0.00	3.00K	50.00K	51.00K	59.00K	59.00K	32.00K	43.00K	60.00K	160.00K	0.00	0.00	0.00	0.00	0.00	270.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	2.45M	0.00	0.00	0.00	165.00K	0.00	115.00K	128.00K	154.00K	170.00K	291.00K	523.00K	896.00K	1.33M	901.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	5.12M	4.51M	3.64M	3.10M	3.70M	2.46M	3.35M	2.89M	2.40M	2.46M	2.15M	1.96M	2.27M	2.41M	3.74M	3.64M	2.51M	2.37M	2.47M	2.69M	2.90M	3.10M	3.62M	3.73M	4.20M	4.40M	3.50M	2.30M	1.50M	1.30M	900.00K	800.00K	600.00K	500.00K	900.00K	1.50M
EBITDA	33.22M	48.31M	36.98M	9.86M	15.55M	9.06M	-277.00K	-9.66M	-3.08M	-5.14M	3.44M	1.75M	5.49M	-379.00K	364.00K	-17.13M	-12.19M	-10.88M	-7.32M	-7.34M	-3.62M	-4.01M	-6.93M	-16.45M	8.20M	11.00M	12.80M	12.40M	8.60M	6.80M	2.80M	-3.80M	-10.60M	-3.60M	-2.70M	-1.20M
EBITDA Ratio	10.30%	17.59%	17.33%	5.51%	10.70%	7.98%	-1.21%	-11.27%	-2.76%	-6.85%	4.70%	2.54%	8.10%	-0.28%	0.10%	-22.15%	-18.54%	-20.45%	-17.06%	-14.63%	-6.12%	-4.81%	1.54%	-21.19%	13.39%	19.00%	23.06%	27.96%	23.05%	21.90%	10.45%	-63.73%	-244.19%	-313.33%	-60.00%	-19.12%
Operating Income	28.10M	43.80M	33.34M	6.77M	11.85M	6.60M	-3.63M	-12.66M	-5.34M	-8.03M	700.00K	-1.22M	2.78M	-2.60M	-3.73M	-20.39M	-14.12M	-13.60M	-10.81M	-10.16M	-6.53M	-7.11M	-17.79M	-20.18M	4.00M	6.60M	9.30M	10.10M	7.10M	5.50M	1.90M	-4.60M	-11.20M	-4.10M	-3.60M	-2.70M
Operating Income Ratio	8.71%	15.40%	14.47%	4.14%	7.89%	5.32%	-4.01%	-15.35%	-6.92%	-10.70%	0.97%	-1.91%	4.43%	-4.73%	-4.95%	-27.22%	-23.78%	-24.17%	-21.07%	-19.65%	-12.93%	-14.74%	-35.40%	-37.38%	6.78%	12.18%	21.88%	23.93%	20.46%	20.07%	9.45%	-45.10%	-260.47%	-91.11%	-80.00%	-39.71%
Total Other Income/Expenses	5.60M	1.75M	-2.04M	1.50M	1.17M	44.00K	1.34M	211.00K	-268.00K	-618.00K	414.00K	701.00K	-79.00K	-1.08M	-741.00K	-1.29M	-1.04M	95.00K	854.00K	-88.00K	-705.00K	-1.01M	2.99M	-5.30M	-900.00K	-500.00K	2.40M	100.00K	300.00K	600.00K	700.00K	2.70M	-100.00K	10.00M	0.00	-800.00K
Income Before Tax	33.70M	45.80M	31.30M	8.27M	13.03M	6.64M	-2.30M	-12.44M	-5.61M	-8.65M	1.11M	-519.00K	2.70M	-3.68M	-4.71M	-21.67M	-15.16M	-13.51M	-9.96M	-10.25M	-7.16M	-8.12M	-18.24M	-25.48M	3.10M	6.10M	11.70M	10.20M	7.40M	6.10M	2.60M	-1.90M	-11.30M	5.90M	0.00	-3.50M
Income Before Tax Ratio	10.45%	16.11%	13.58%	5.06%	8.67%	5.36%	-2.53%	-15.10%	-7.27%	-11.53%	1.54%	-0.81%	4.31%	-6.70%	-6.25%	-28.94%	-25.53%	-24.00%	-19.41%	-19.82%	-14.19%	-16.84%	-36.31%	-47.20%	5.25%	11.25%	27.53%	24.17%	21.33%	22.26%	12.94%	-18.63%	-262.79%	131.11%	0.00%	-51.47%
Income Tax Expense	12.35M	6.80M	6.80M	2.35M	-1.02M	1.67M	-157.00K	-315.00K	928.00K	-253.00K	716.00K	1.24M	1.36M	432.00K	1.49M	1.52M	843.00K	1.54M	1.24M	1.06M	1.13M	8.96M	-3.55M	-6.58M	900.00K	2.00M	4.30M	3.30M	-100.00K	-2.20M	100.00K	500.00K	100.00K	2.60M	800.00K	200.00K
Net Income	21.35M	39.67M	27.51M	5.91M	14.05M	4.97M	-2.14M	-12.13M	-6.53M	-8.39M	398.00K	-1.76M	1.35M	53.00K	-6.20M	-23.20M	-16.00M	-15.04M	-11.18M	-11.33M	-8.36M	-17.16M	-14.83M	-18.90M	2.20M	2.40M	7.40M	6.90M	7.50M	8.30M	2.50M	-5.10M	-11.30M	3.50M	-4.40M	-3.80M
Net Income Ratio	6.62%	13.95%	11.94%	3.62%	9.35%	4.01%	-2.36%	-14.71%	-8.47%	-11.19%	0.55%	-2.76%	2.15%	0.10%	-8.23%	-30.97%	-26.95%	-26.73%	-21.78%	-21.93%	-16.56%	-35.56%	-29.53%	-35.01%	3.73%	4.43%	17.41%	16.35%	21.61%	30.29%	12.44%	-50.00%	-262.79%	77.78%	-97.78%	-55.88%
EPS	0.44	0.83	0.52	0.13	0.32	0.11	-0.05	-0.30	-0.17	-0.22	0.01	-0.05	0.04	0.00	-0.19	-0.79	-0.57	-0.60	-0.47	-0.58	-0.47	-1.00	-0.87	-1.23	0.15	0.18	0.57	0.50	0.55	0.84	0.21	-0.50	-1.22	1.44	-1.59	-1.52
EPS Diluted	0.43	0.80	0.50	0.12	0.30	0.11	-0.05	-0.30	-0.17	-0.22	0.01	-0.05	0.04	0.00	-0.19	-0.79	-0.57	-0.60	-0.47	-0.58	-0.47	-1.00	-0.87	-1.23	0.15	0.17	0.53	0.50	0.55	0.80	0.20	-0.50	-1.22	1.44	-1.59	-1.52
Weighted Avg Shares Out	48.52M	47.99M	47.21M	45.61M	44.49M	45.16M	41.00M	40.33M	38.43M	38.09M	36.71M	35.26M	35.43M	34.83M	32.50M	29.47M	28.12M	25.23M	23.70M	19.60M	17.70M	17.14M	17.00M	15.37M	14.67M	13.33M	12.98M	13.80M	13.64M	9.88M	11.90M	10.20M	9.29M	4.06M	2.76M	2.50M
Weighted Avg Shares Out (Dil)	49.43M	49.38M	49.46M	47.95M	46.90M	45.26M	41.00M	40.33M	39.26M	38.09M	38.61M	36.25M	36.88M	34.83M	32.50M	29.47M	28.12M	25.23M	23.70M	19.60M	17.70M	17.16M	17.00M	15.37M	14.67M	14.12M	13.96M	13.80M	13.64M	10.38M	12.50M	10.20M	9.29M	4.06M	2.76M	2.50M

Don't Overlook Staar Surgical (STAA) International Revenue Trends While Assessing the Stock

May 13, 2024zacks.com

Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

STAAR Surgical Company (STAA) Q1 2024 Earnings Call Transcript

May 7, 2024seekingalpha.com

STAAR Surgical Company (NASDAQ:STAA ) Q1 2024 Results Conference Call May 7, 2024 4:15 PM ET Company Participants Brian Moore - VP, IR Tom Frinzi - President, CEO Patrick Williams - CFO Conference Call Participants Margaret Kaczor - William Blair...

Staar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to Say

May 7, 2024zacks.com

The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Wall Street's Insights Into Key Metrics Ahead of Staar Surgical (STAA) Q1 Earnings

May 6, 2024zacks.com

Beyond analysts' top -and-bottom-line estimates for Staar Surgical (STAA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

May 1, 2024businesswire.com

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and...

STAAR Surgical to Report First Quarter Results on May 7, 2024

April 29, 2024businesswire.com

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first...

Star Surgical Shines as U.S. Outlook Improves for 2024

April 16, 2024marketbeat.com

STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable Collamer Lenses (ICL) used for the treatment of nearsightedness (myopia), refractive...